癌症合并COVID-19住院患者静脉血栓栓塞症风险评估模型CoVID-TE
基于COVID-19与癌症联盟注册研究(CCC19)中2804例癌症合并COVID-19住院患者,静脉血栓栓塞症(VTE)和动脉血栓栓塞症(ATE)发生率分别为7.6%和3.9%。研究构建并内部验证了简化的VTE风险评估模型CoVID-TE,将患者分为低危(0-2分)和高危(3分及以上),VTE发生率分别为4.1%和11.3%(c统计量0.67,95%CI 0.63-0.71)。
要点
- 癌症合并COVID-19住院患者VTE发生率7.6%,ATE发生率3.9%。
- 近期接受抗癌治疗者VTE发生率更高,但ATE未见升高。
- CoVID-TE模型(0-2分低危 vs 3分及以上高危)可区分VTE风险。
核心结论
- 癌症合并COVID-19住院患者血栓风险升高,CoVID-TE风险评估模型有助于VTE预测。
研究设计与样本
- 基于COVID-19与癌症联盟注册研究(CCC19)队列,分析2020年3月17日至2020年11月30日期间2804例癌症合并COVID-19住院患者。
- 采用多变量逻辑回归构建VTE风险模型,并通过bootstrap进行内部验证。
主要发现
- VTE发生率为7.6%,ATE发生率为3.9%。
- 近期接受抗癌治疗的患者VTE发生率更高,但ATE未见升高。
- CoVID-TE模型将患者分为低危(0-2分,n=1423)和高危(3分及以上,n=1034),VTE发生率分别为4.1%和11.3%(c统计量0.67,95%CI 0.63-0.71)。
- 模型在入院前未使用抗凝剂和未直接入住ICU的中度病情患者亚组中表现相似。
关键数值与推荐
- CoVID-TE模型评分项:原Khorana评分为高危至极高危的癌症亚型+1分,VTE病史+2分,ICU入住+2分,D-二聚体升高+1分,近期全身抗癌治疗+1分,非西班牙裔 ethnicity +1分。
- 风险分层:0-2分为低危,3分及以上为高危。
临床怎么用
- 可用于癌症合并COVID-19住院患者的VTE实时风险分层,辅助临床决策。
局限性
- 模型为内部验证,需外部验证确认其普遍适用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hospitalized patients with COVID-19 have increased risks of venous (VTE) and arterial thromboembolism (ATE). Active cancer diagnosis and treatment are well-known risk factors; however, a risk assessment model (RAM) for VTE in patients with both cancer and COVID-19 is lacking. OBJECTIVES: To assess the incidence of and risk factors for thrombosis in hospitalized patients with cancer and COVID-19. METHODS: Among patients with cancer in the COVID-19 and Cancer Consortium registry (CCC19) cohort study, we assessed the incidence of VTE and ATE within 90 days of COVID-19-associated hospitalization. A multivariable logistic regression model specifically for VTE was built using a priori determined clinical risk factors. A simplified RAM was derived and internally validated using bootstrap. RESULTS: From March 17, 2020 to November 30, 2020, 2804 hospitalized patients were analyzed. The incidence of VTE and ATE was 7.6% and 3.9%, respectively. The incidence of VTE, but not ATE, was higher in patients receiving recent anti-cancer therapy. A simplified RAM for VTE was derived and named CoVID-TE (Cancer subtype high to very-high risk by original Khorana score +1, VTE history +2, ICU admission +2, D-dimer elevation +1, recent systemic anti-cancer Therapy +1, and non-Hispanic Ethnicity +1). The RAM stratified patients into two cohorts (low-risk, 0-2 points, n = 1423 vs. high-risk, 3+ points, n = 1034) where VTE occurred in 4.1% low-risk and 11.3% high-risk patients (c statistic 0.67, 95% confidence interval 0.63-0.71). The RAM performed similarly well in subgroups of patients not on anticoagulant prior to admission and moderately ill patients not requiring direct ICU admission. CONCLUSIONS: Hospitalized patients with cancer and COVID-19 have elevated thrombotic risks. The CoVID-TE RAM for VTE prediction may help real-time data-driven decisions in this vulnerable population.
引用
- Li A, Kuderer NM, Hsu CY, et al. The CoVID-TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19. J Thromb Haemost. 2021. PMID: 34260813. doi:10.1111/jth.15463
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。